FREQ Profile
Frequency Therapeutics Inc (FREQ) is a biotechnology company that focuses on developing small molecule drugs to treat hearing loss and balance disorders. The company's lead drug candidate, FX-322, is designed to regenerate damaged hair cells in the inner ear, which are responsible for hearing and balance.
FX-322 is currently in Phase 2a clinical trials for sensorineural hearing loss, which is the most common form of hearing loss and is caused by damage to the hair cells in the inner ear. The company believes that FX-322 has the potential to restore hearing without the need for cochlear implants or hearing aids.
In addition to FX-322, Frequency Therapeutics is also developing a pipeline of other small molecule drugs for various indications, including inflammatory bowel disease, multiple sclerosis, and respiratory disease. The company's approach is based on using its proprietary "progenitor cell activation" technology to stimulate the body's natural ability to repair and regenerate damaged tissues.
Frequency Therapeutics was founded in 2015 and is headquartered in Woburn, Massachusetts. The company went public in 2019 and is listed on the Nasdaq Global Select Market under the ticker symbol FREQ.
|
